Drug Trial Radar · NCT00128102
Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)
Last checked: Nov 20, 2026Latest source record: Oct 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
661
Actual
Start
Jun 30, 2005
Primary completion
Jul 15, 2011
Study completion Nov 21, 2011
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Aug 9, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to assess the efficacy and safety of an oral investigational drug suberoylanilide hydroxamic acid (vorinostat, MK-0683) compared to placebo, in the treatment of participants with advanced malignant pleural mesothelioma who have failed at least one prior chemotherapy regimen. The primary hypotheses are the following: (1) vorinostat improves overall survival (OS) compared to placebo (2) vorinostat is generally safe and well tolerated.
Conditions
- Mesothelioma
- Lung Cancer
Interventions
VorinostatDrug
Vorinostat 100 mg oral capsules
PlaceboDrug
Vorinostat-matching placebo oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
- Number of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)Time frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
- Number of Participants Who Experienced an AETime frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
- Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.